Urological Cancer including bladder, kidney (in both male and female), prostate and testicular (in male) are among the most common cancers. Approximately more than 550,000 new cases reported annually, in which about 40 - 80% of all patients in terminal stage of urological cancers experience persistent and disabling pain. Despite its prevalence, half of these patients don’t receive adequate analgesia and pain management by clinicians. Furthermore, the characteristic of urological cancer-related pain varies in intensity and duration. Hence, there’s a need for personalised analgesic therapy for pain management in patients with urological cancers based on their clinical conditions and the specific type of cancer.
This article collection aims to deliver high quality research in support of Urological Cancer Awareness Month 2022, with a focus on pain management in patients with advanced-stage urological cancers. Specifically, pain from urogenital tumors with or without bone metastasis that is nociceptive and/or neuropathic in nature.
We welcome the submission of manuscripts including, but not limited to, the following topics:
1. Treatments for metastatic bone pain in patients with urological cancers
2. The role of sensory nerves in cancer-associated bone pain and bone innervation sensitisation in patients with urological cancers
3. Management of side effects from analgesic interventions in patients with urological cancers
4. Efficacy of currently available bisphosphonates in cancer-related bone pain
5. Regional and/or neuraxial techniques for treatments of urological cancer pain
6. Stereotactic radiotherapy in ovarian cancer critical oligoprogression during PARP inhibitors maintenance therapy
Urological Cancer including bladder, kidney (in both male and female), prostate and testicular (in male) are among the most common cancers. Approximately more than 550,000 new cases reported annually, in which about 40 - 80% of all patients in terminal stage of urological cancers experience persistent and disabling pain. Despite its prevalence, half of these patients don’t receive adequate analgesia and pain management by clinicians. Furthermore, the characteristic of urological cancer-related pain varies in intensity and duration. Hence, there’s a need for personalised analgesic therapy for pain management in patients with urological cancers based on their clinical conditions and the specific type of cancer.
This article collection aims to deliver high quality research in support of Urological Cancer Awareness Month 2022, with a focus on pain management in patients with advanced-stage urological cancers. Specifically, pain from urogenital tumors with or without bone metastasis that is nociceptive and/or neuropathic in nature.
We welcome the submission of manuscripts including, but not limited to, the following topics:
1. Treatments for metastatic bone pain in patients with urological cancers
2. The role of sensory nerves in cancer-associated bone pain and bone innervation sensitisation in patients with urological cancers
3. Management of side effects from analgesic interventions in patients with urological cancers
4. Efficacy of currently available bisphosphonates in cancer-related bone pain
5. Regional and/or neuraxial techniques for treatments of urological cancer pain
6. Stereotactic radiotherapy in ovarian cancer critical oligoprogression during PARP inhibitors maintenance therapy
